Other Hematologic Disorders

Other Hematologic Disorders
- Sickle Cell
- GVHD
  - Acute
    - Prevention
    - VICCCTT25042
      Phase 2 Study of Ruxolitinib-Based Primary Treatment for Acute GVHD
    - AML Post-SCT in CR1
  - Chronic
    - 1st Line
      - No Current Trials
    - 2nd Line and Above
- Other
  - VICC-ITHEM23019
    Phase II Study of Inflamm Modif of Canakinumab to Prevent Leukemic Progression of CCUS
  - VICCCTT1875
    A Phase 3 Study of Tabelecleucel for Subjects with Epstein-Barr Virus-Associated Post-Transplant Lym
    - Off the shelf allogeneic EBV specific T cells for PTLD
      
      Key Eligibility:
      
      Prior allo-HCT required
      Progressive disease after 3 doses of Rituxan +- chemo or stable disease after 4 doses of Rituxan
      CNS disease must be controlled
      
      Schedule:
      
      Outpatient IV injection day 1, 8, 15 of 35 day cycle. Up to 4 cycles allowed.